Prot #CA2097A8: Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer ≥ 2 cm with Safety Run-in, Assessing Nivolumab + Palbociclib + Anastrozole (CheckMate 7A8)

Project: Research project

Project Details

StatusActive
Effective start/end date2/9/212/9/24

Funding

  • Bristol-Myers Squibb Company (Prot #CA2097A8)